Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis market Read more
US FDA grants Orphan Drug Designation to Zydus’ Saroglitazar for primary biliary cholangitis treatment Read more
USFDA grants Zydus fast track designation for Saroglitazar to treat primary biliary cholangitis Read more